CASI Pharmaceuticals, Inc.
CASI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $34 | $43 | $30 |
| % Growth | -15.8% | -21.4% | 42.9% | – |
| Cost of Goods Sold | $17 | $14 | $16 | $13 |
| Gross Profit | $11 | $20 | $27 | $18 |
| % Margin | 39.1% | 59.2% | 63.3% | 58.4% |
| R&D Expenses | $9 | $10 | $16 | $14 |
| G&A Expenses | $24 | $25 | $23 | $24 |
| SG&A Expenses | $41 | $42 | $38 | $38 |
| Sales & Mktg Exp. | $18 | $16 | $14 | $15 |
| Other Operating Expenses | $0 | -$7 | $0 | $6 |
| Operating Expenses | $51 | $45 | $54 | $59 |
| Operating Income | -$40 | -$25 | -$26 | -$42 |
| % Margin | -138.8% | -74% | -61.5% | -137.6% |
| Other Income/Exp. Net | $2 | -$1 | -$12 | $6 |
| Pre-Tax Income | -$38 | -$26 | -$38 | -$36 |
| Tax Expense | $1 | -$0 | $2 | $0 |
| Net Income | -$39 | -$27 | -$41 | -$37 |
| % Margin | -137.6% | -79.5% | -95.1% | -121.5% |
| EPS | -2.56 | -2.02 | -3.01 | -2.69 |
| % Growth | -26.7% | 32.9% | -11.9% | – |
| EPS Diluted | -2.56 | -2.02 | -3.01 | -2.69 |
| Weighted Avg Shares Out | 15 | 13 | 14 | 14 |
| Weighted Avg Shares Out Dil | 15 | 13 | 14 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $4 | $2 | $2 |
| EBITDA | -$35 | -$22 | -$24 | -$33 |
| % Margin | -122.2% | -63.6% | -55.8% | -110.7% |